$TMDX - Bottom is in, higher from here!If you are a NASDAQ:TMDX bull you are going to want to see this!
In my opinion, we've just bottomed!
🎯$80
Not financial advice
TMDX
TransMedics Group ($TMDX): Saving Lives and Your Portfolio?1/ 🚨 TransMedics Group ( NASDAQ:TMDX ): Saving Lives and Your Portfolio? Or Just Priced for Perfection?
With a 64% sales jump and newfound profitability, NASDAQ:TMDX is shaking up organ care. But with sky-high valuations, is it the future or just another stock on life support? Let’s dissect. 💉📈
2/ 🌟 Sales That Keep Beating
In Q3 2024, NASDAQ:TMDX pulled in $108.8M in sales—a 64% boost from last year. Q2? A jaw-dropping $114.31M, more than double the prior year. This growth is the kind that gets Wall Street’s pulse racing. 📊💰
3/ 💹 Profits Resuscitated
They’ve gone from bleeding cash to banking it—$4.2M in Q3 2024, or $0.12/share. And Q2? An even stronger $12.19M. They’ve traded losses for green pastures, but can they keep it alive? ✅
4/ 📉 Margins Need CPR
Profit margins slipped to 56% in Q3 from 61% last year. Translation? They’re making more but keeping less. Efficiency is a work in progress—like a transplant waiting for the right match. 🔧📊
5/ 💸 Cash for Days
With $330.1M in the bank (as of Sept. 2024), NASDAQ:TMDX has a war chest for innovation and growth. They’ve got the funds to play big—but will it pay off? 💰🏦
6/ 🔮 Big Goals, Big Promises
Sales targets for 2024: $425M to $445M. That’s the kind of growth projection that has investors either excited or reaching for the Advil. 🎯
7/ ⚖️ Financial Vital Signs
They’ve got an enviable short-term health ratio of 8.20 but a debt-to-equity ratio of 2.47. Return on equity? Solid at 19.41%. But return on invested capital? Just 3.05%. Efficient? Not quite. 💧🔄
8/ ⚠️ The Price Tag
NASDAQ:TMDX isn’t cheap: a trailing P/E of 97.54 and forward P/E of 72.35. Investors expect miracles at this valuation. Add a beta of 2.07, and this stock has more swings than a playground. 📈⚡️
9/ 🔎 SWOT Snapshot
Strengths: Revolutionary Organ Care System, market dominance, first taste of profitability.
Weaknesses: High expectations, reliance on organ donation rates.
Opportunities: Expanding globally and meeting rising transplant demand.
Threats: Regulatory hurdles and competitors with shiny new tech.
10/ 💡 What’s Your Take on NASDAQ:TMDX ?
With revolutionary tech and rapid growth, NASDAQ:TMDX has potential—but risks remain. What’s your call?
Buy for the long term 📈
Hold and watch growth 🔄
Too risky, sell or avoid 🚫
Let us know in the comments.
Catching the TransMedics Group - $TMDX Falling KnifeTransMedics Group - NASDAQ:TMDX
For current and new shareholders here is your buying range for this company.
This could be the bounce that sends us back towards ATH's. But, if we were to fall lower I think it would be capped out around the 200MA.
DCA Buying Range: $55-$90
AVP GAP Fill to $134
NFA
TMDX - Quick lookBull and Bear case laid out. I may do an explanation later but too lazy right now.
Watch ~38 for a pivot.
